OncoTherapy Science (OTS) announced on February 1 that it has signed a joint research agreement with Carna Biosciences (CARNA) and CrystalGenomics (CG).
Last Updated on Monday, 13 February 2006 05:16 Written by admin Wednesday, 1 February 2006 04:59
Tokyo, Feb 1, 2006 (JCN) – OncoTherapy Science (OTS) announced on February 1 that it has signed a joint research agreement with Carna Biosciences (CARNA) and CrystalGenomics (CG).
The three companies will collaborate in searching low-molecular compounds that inhibit the activities of two different cancer-specific protein kinases possessed by OTS. Specifically, CARNA will be in charge of protein expression, assay formulation and screening while CG will handle virtual screening of compounds, compound library creation and X-ray crystallographic analysis.
Further, using the newly-identified low-molecular compounds, the three companies will strive to develop compound candidates for cancer treatment. The partners will co-own rights to the new compounds, but OTS will be in charge of commercializing them.
Source: JCNnetwork
Main Menu
- Home
- About Bioscreening.net
- Glossary
- Biotechnology Glossary A-I
- Biotechnology Glossary J-Q
- Biotechnology Glossary R-Z
- Bird Flu
- Cheminformatic Glossary
- Endotoxins
- Fullerenes
- Genipin
- Gossypol (Gossipol)
- Grants, Venture Capital, and Government Funding
- High-throughput screening
- Lipinski Rule-of-Five
- Mumie
- Natural Medicine
- Rule-of-Three (Ro3)
- Targeted Libraries
- Web Directory